14-Day repeat-dose oral toxicity evaluation of oxazyme in rats and dogs

International Journal of Toxicology

Volumn 29, Issue 1, 2010, Pages 20-31

  Cowley, Aaron B ^a   Poage, Duane W ^b   Dean, Robin R ^c   Meschter, Carol L ^c   Ghoddusi, Majid ^c   Li, Qing Shan ^a   Sidhu, Harmeet ^d  

^a Captozyme LLC   (United States)

^b MPI RESEARCH   (United States)

^c Department of Research Services   (United States)

^d Oxthera Inc   (United States)

Author keywords

Kidney stone; No observed adverse effect level; OC4; Oxalate; Oxazyme; Safety; Toxicity

Indexed keywords

OXALATE DECARBOXYLASE; OXALIC ACID DERIVATIVE; OXAZYME; UNCLASSIFIED DRUG; CARBOXYLYASE; RECOMBINANT PROTEIN;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CECUM; COLON; CONTROLLED STUDY; DOG; DUODENUM; ELECTROCARDIOGRAPHY; EYE EXAMINATION; FEMALE; FOOD INTAKE; HEMATOLOGY; HISTOPATHOLOGY; ILEUM; IMMUNOGENICITY; JEJUNUM; LIVER; LUNG; MALE; NONHUMAN; ORGAN WEIGHT; OVARY; RAT; RISK ASSESSMENT; TOXICOKINETICS; TOXICOLOGY; URINALYSIS; ANIMAL; BLOOD ANALYSIS; BLOOD EXAMINATION; DRUG SURVEILLANCE PROGRAM; ORAL DRUG ADMINISTRATION; TOXICITY TESTING;

ANIMALIA; BACILLUS SUBTILIS; CANIS FAMILIARIS; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD CHEMICAL ANALYSIS; CARBOXY-LYASES; DOGS; FEMALE; HEMATOLOGIC TESTS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RECOMBINANT PROTEINS; TOXICITY TESTS; URINALYSIS;

EID: 77949898152     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809353611     Document Type: Article

References (37)

1. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111:1006-1009.
2. Worcester E, Parks JH, Josephson MA. Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int. 2003;64:2204-2213. (Pubitemid 37449556)
3. Jungers P, Joly D, Barbey F. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004;44:799-805. (Pubitemid 39445911)
4. Johnson CM, Wilson DM, O'Fallon WM. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int. 1979;16:624-631.
5. Stamatelou KK, Francis ME, Jones CA. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-1823.
6. Hesse A, Schneeberger W, Engfeld S, et al. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2] oxalate. J Am Soc Nephrol. 1999;10(suppl 14):S329-S333. (Pubitemid 29498574)
7. Kathiara M, Wood DA, Evans CE. Detection and partial characterization of oxalate decarboxylase from agaricus bisporus. Mycol Res. 2000;104:345-350. (Pubitemid 30437901)
8. Azam M, Kesarwani M, Chakraborty S, et al. Cloning and characterization of the 5'-flanking region of the oxalate decarboxylase gene from Flammulina velutipes. Biochem J. 2002;367:67-75. (Pubitemid 35176892)
9. Morinaga T, Yamaguchi M, Makino Y, et al. Functional myoinositol catabolic genes of Bacillus subtilis natto are involved in depletion of pinitol in natto (fermented soybean). Biosci Biotechnol Biochem. 2006;70:1913-1920. (Pubitemid 44285425)
10. Reinhardt LA, Svedruzic D, Cleland WW, et al. Heavy atom isotope effects on the reaction catalyzed by the oxalate decarboxylase from Bacillus subtilis. J Am Chem Soc. 2003;125:1244-1252. (Pubitemid 36159835)
11. Tanner A, Bowater L, Fairhurst SA, et al. Oxalate decarboxylase requires manganese and dioxygen for activity: overexpression and characterization of Bacillus subtilis YvrK and YoaN. J Biol Chem. 2001;276:43627-43634. (Pubitemid 37383923)
12. Holmes RP, Kennedy M. Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int. 2000;57:1662-1667. (Pubitemid 30207924)
13. US FDA. Good Laboratory Practice Regulations for Non-clinical Laboratory Studies, Federal Register 21 CFR Part 58, June 20, 1979 and all subsequent amendments. Silver Spring, Md: US Food and Drug Administration; 1979.
14. OECD. Series on Principles of Good Laboratory Practice and Compliance Monitoring, ENV/MC/CHEM(98)17, 1981, and all subsequent amendments. Paris, France: Organisation for Economic Co-operation and Development; 1981.
15. US-FDA. Redbook 2000. Toxicological Principles for the Safety Assessment of Food Ingredients: Office of Food Additive Safety. Silver Spring, Md: US Food and Drug Administration; 2003.
16. OECD. Guideline for the Testing of Chemicals 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents. Paris, France: Organisation for Economic Co-operation and Development; 1995.
17. OECD. Guideline for the Testing of Chemicals 409: Repeated Dose 90-Day Oral Toxicity Study in Non-rodents. Paris, France: Organisation for Economic Co-operation and Development; 1998.
18. US-FDA. Final Rules: Animal Welfare, Federal Register 9 CFR Part 1, August 31, 1989 and all subsequent amendments. Silver Spring, Md: US Food and Drug Administration.
19. US-USDA. Animal Welfare Act. 7 USC 2131. August 24, 1966 and all subsequent amendments. Washington, DC: US Department of Agriculture; 1966.
20. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
21. Moser VC, McCormick JP, Creason JP, et al. Comparison of chlordimeform and carbaryl using a functional observational battery. Fund Appl Toxicol. 1988;11:189-206.
22. Moser VC, Ross JF. US EPA/AIHC training video and reference manual for a functional observational battery. Washington, DC: US Environmental Protection Agency; 1996.
23. Meyer OA, Tilson HA, Byrd WC, et al. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol. 1979;1:233-236.
24. Edwards PM, Parker VH. A simple, sensitive and objective method for early assessment of acrylamide neuropathy in rats. Toxicol Appl Pharmacol. 1977;40:589-591.
25. Ankier SI. New hot plate tests to quantify anti-nociceptive and narcotic antagonist activities. Eur J Pharmacol. 1974;27:1-4.
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2(R1). Current Step 4 version. Parent Guideline dated October 27, 1994 (Complementary Guideline on Methodology dated November 6, 1996 incorporated November 2005). Geneva, Switzerland: International Conference on Harmonisation.
27. Moore KL, Barr ML. Nuclear morphology, according to sex, in human tissues. Acta Anat. 1954;21:197-208.
28. Welch BL. The generalization of "Student's" problem when several different population variances are involved. Biometrika. 1947;34:28-35.
29. Levene H. Robust tests for equality of variances. In Olkin I et al, eds. Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford, Calif: Stanford University Press; 1960:78-292.
30. Tukey JW. Exploratory Data Analysis. Reading, PA: Addison Wesley; 1977.
31. Kruskal WH and Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952;47:583-621.
32. Yamada C, Yamashita Y, Seki R, et al. Digestion and gastrointestinal absorption of the 14-16-kDa rice allergens. Biosci Biotechnol Biochem. 2006;70:1890-1897. (Pubitemid 44285422)
33. Radauer C, Breiteneder H. Evolutionary biology of plant food allergens. J Allergy Clin Immunol. 2007;120:518-525. (Pubitemid 47320773)
34. Jahn E-M, Schneider CK. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. New Biotechnol. 2009;25:280-286.
35. McMartin KE, Martin-Amat G, Makar AB, Tephly TR. Methanol poisoning: role of formate metabolism in the monkey. J Pharmacol Exp Ther. 1977;201:564-572.
36. Clay KL, Murphy RC, Watkins WD. Experimental methanol toxicity in the primate. Toxicol Appl Pharmacol. 1975;34:49-61.
37. Malorny G. Acute and chronic toxicity of formic acid and formats. Z Ernaehrungswiss. 1969;9:443-449.